Digene (Gaithersburg, Maryland) last month reported that Italy has become the first country to launch a government-sponsored cervical cancer screening program using the HPV test as a frontline diagnostic tool, followed by Pap test cytology for women who are found to carry the human papillomavirus (HPV). The program, organized by the healthcare unit ASL Roma G, the largest local health unit in Italy, focuses on women living in Tivoli, outside of Rome.

Digene says that its HPV Test, which uses the company’s Hybrid Capture II (hc2) technology, is the only test for detecting the presence of high-risk types of HPV, the cause of cervical cancer, that is clinically validated and both FDA-approved and CE-marked. In the U.S., it is approved for routine use along with a Pap in women age 30 and older. However, since clinical evidence has shown that HPV infection is necessary for the development of cervical cancer and that HPV testing can identify women at risk for developing the disease, Roma G has decided to test women age 25-64 for high-risk types of the virus before administering a Pap test.

A number of medical experts, including the authors of a recent consensus paper on HPV published in the journal Vaccine, have predicted that this is the future direction for cervical cancer screening.

In the pilot phase of the program, 26,000 women in the targeted age range who live in the jurisdiction of the Roma G unit are being recruited for HPV testing via a letter and educational information. Once the pilot is complete and outcomes are assessed, primary HPV screening will be considered for expansion to all eligible women in the area.

“The [Italian] Public Health Agency has identified our ASL Roma G unit as the pilot center for the first use of the HPV test as a first-level screening tool,” said Dr. Maria Concetta Tufi, who is responsible for the screening program of ASL Roma G. “It is a unique approach not only for Italy but for the whole world.”

She added, “It’s an innovation destined to radically change the approach to cervical cancer prevention, with an ambitious objective to eliminate a disease that kills approximately 300,000 women around the world ever year, including 2,000 in Italy.”

The Digene HPV Test uses molecular technology to identify the presence of the DNA of 13 high-risk types of HPV. The company said research has shown that when used alone, the sensitivity of Pap cytology is highly variable, ranging from 50% to 85%. In contrast, it said the sensitivity of the Digene HPV Test has been proven in large-scale clinical trials to be 95% to 100%.

Wright Medical Group to close facility in France

Citing completion of a lengthy review of the company’s worldwide operations, Wright Medical Group (Arlington, Tennessee), said it is planning to close its manufacturing and distribution facility located in Toulon, France. Wright, a manufacturer of reconstructive joint devices and biologics, said it has entered into discussions regarding the facility’s closure with the local staff representatives of the approximately 130 Toulon-based employees affected.

Saying it expects that the facility closure will be completed by year-end, Wright will transfer all Toulon production to its existing manufacturing facility in Arlington, while the majority of the distribution and administrative activities currently being performed there will be transferred to the company’s European headquarters in Amsterdam, the Netherlands.

CEO and President Gary Henley said during a conference call that the Toulon facility, which came to the company as part of a 1999 acquisition, primarily produces hip products for the European market. He said the plant closure would have no impact on the company’s European business, which he characterized as “quite healthy.”

“After careful analysis and consideration, we have reached a clear conclusion with respect to our worldwide capacities. The closing of our Toulon operations, while painful to all of us, is necessary to ensure the long-term competitiveness of the company,” Henley said in a company statement.

Henley said during the conference call that the pre-tax charges related to the closing of the Toulon facilities will be in the range of $20 million to $25 million, including both cash and non-cash items such as asset impairment charges, severance and benefits costs, external legal and professional fees, and other costs. A portion of those charges are expected to be recorded in each of the second, third and fourth quarters of 2007.

Responding to a question by market analyst Taylor Harris of JP Morgan (New York), Henley said that production at the French facility is ongoing, but will be halted in “the next few weeks.” He said the company has about a year’s supply of the products that have been produced there on hand and that it has more than enough available production capacity at the Tennessee facility to replace that lost by the Toulon shutdown.

Henley noted that an expansion program already was under way at the Arlington facility. He added that there would be “no impact” on European sales and distribution, which now will be handled out of Amsterdam.

Medicsight, Viatronix release virtual colonoscopy with CAD

Viatronix (Stony Brook, New York), a developer of diagnostic 3D imaging software, and Medicsight (London), a developer of computer-aided detection (CAD) technologies, reported the European commercial release of their integrated “virtual colonoscopy” products with CAD.

Medicsight presented the integrated solution at the annual congress of the European Society of Gastrointestinal and Abdominal Radiology in Lisbon, Portugal, last month.

The Viatronix V3D-Colon, integrated with Medicsight’s CAD system for performing virtual colonoscopy, has received the CE mark. The integrated Viatronix system aids physicians in the early detection and identification of polyps and has been tested at more than 25 sites across Europe, according to the company.

“The integrated products provide additional tools, to improve the speed and efficiency of radiologists’ workflow,” said Zaffar Hayat, president of Viatronix.

Medicsight CEO David Sumner said, “We are confident that the integrated solution will create an ideal workflow and optimize reading times for end user productivity, giving Viatronix and Medicsight the opportunity to capitalize on the ever increasing customer demand for virtual colonoscopy with CAD.”

The Viatronix V3D-Colon allows physicians to interactively view the colon as reconstructed from a computed tomography (CT) scan, providing visualization of the entire colon where polyps or other lesions may be located.

Viatronix said it is the only system on the market that is backed by a multi-center clinical trial showing 93.9% sensitivity and 92.2% specificity for adenomatous polyps sized 8 mm and larger.

Medicsight ColonCAD API is an image-analysis software tool designed to be used with CT colonography scans to assist radiologists in detecting and measuring potential colorectal polyps. ColonCAD is integrated within the advanced 3D visualization and picture archiving and communications system platforms of various imaging equipment partners.

Cleveland Clinic to manage health facilities network in Abu Dhabi

The Cleveland Clinic (Cleveland, Ohio) reported an agreement with the Health Authority of Abu Dhabi to manage Sheikh Khalifa Medical City (SKMC), a network of healthcare facilities in Abu Dhabi, capital city of the United Arab Emirates.

SKMC consists of 700-bed Sheikh Khalifa Hospital, a 150-bed Behavior Sciences Pavilion and the 100-bed Abu Dhabi Rehabilitation Center, in addition to more than 12 specialized outpatient clinics and nine primary healthcare centers around the city.

Kenneth Ouriel, MD, chairman of Cleveland Clinic’s division of surgery and a vascular surgeon, was named CEO of Sheik Khalifa Medical City.

“As a global healthcare institution, Cleveland Clinic has sought to cultivate opportunities to further expand our presence abroad, sharing state- of-the-art medical practices, procedures and administrative capabilities and raising healthcare standards worldwide,” said Delos (Toby) Cosgrove, president/CEO of the Cleveland Clinic. “In partnering with the Health Authority of Abu Dhabi, we have committed to integrating our medical expertise and best-in-class practices with SKMC to achieve the highest clinical outcomes and enhance research and training.”

He said that the goal of the partnership is “to redefine what is possible in healthcare worldwide.”

Cleveland Clinic and Mubadala Development signed an agreement last September to design and build a new specialty hospital on Al-Suwwa Island within the next three years.

Aurora Imaging establishes Asian subsidiary in Taiwan

Aurora Imaging Technology (North Andover, Massachusetts) has established Aurora Asia as a subsidiary in Taipei, Taiwan. The company manufactures the Aurora 1.5 Tesla Dedicated Breast MRI System, which it said is “the most technologically advanced and only FDA-approved system specifically designed to fight breast cancer.” Aurora said the decision to set up the Taiwanese subsidiary was a direct response to the growing need for advanced breast imaging among Asian women. It said breast cancer is now the leading cause of cancer death in women in Asia.

Data from the Chinese Anti-Cancer Association, the Chinese equivalent of the American Cancer Society, shows that both incidence and death rates of breast cancer in China’s major cities rose by nearly 40% over the last decade.

“Asian women are in dire need of access to the most effective breast imaging technology, such as MRI. By making our Aurora Dedicated Breast MRI System available, we increase the potential to detect cancer at its earliest, most treatable stage. Clinical trials have shown that earlier detection saves lives,” said Olivia Ho Cheng, president and CEO of Aurora

Aurora’s Asian presence began in 2006 with the receipt from the State Food and Drug Administration of China of a Registration Certificate for the Aurora 1.5T Dedicated Breast MRI System. The company said that approval “opened the door for Aurora to move into one of the world’s fastest-growing economies, with a medical device market estimated at close to $3.5 billion.”

Aurora Asia’s president is Dr. Pai-Jung (PJ) Huang, who “brings not only a profound clinical understanding, but also a deep appreciation of the importance and technical challenges to visually present this disease using the MRI imaging technology,” the company said.

Prior to being named president of the new subsidiary, Huang was Aurora’s international clinical director. “It is timely for Aurora to aggressively expand our business throughout Asia, thus allowing us to respond more effectively to the growing demand,” Huang said.

Philips Medical to acquire imaging diagnostic firm in Brazil

Royal Philips Electronics’ Philips Medical Systems (Best, the Netherlands) unit said that it plans to acquire imaging diagnostic company VMI-Sistemas Medicos (VMI; Minas Gerais, Brazil). The transaction is subject to regulatory approval, and was expected to close before the end of the second quarter. No financial details were disclosed.

VMI-Sistemas Medicos was founded in 1985 and has production facilities in Lagoa Santa. It has a presence in the analogical and digital X-ray market, as well as in the cath lab, mammography and ultrasound markets.

“By acquiring VMI, Philips can offer customers in Brazil and across Latin America a more complete medical diagnostic imaging product portfolio,” said Steve Rusckowski, CEO of Philips. “This is our first acquisition of a healthcare company in a developing economy,” he said, “and it endorses the company’s global strategy of focusing on healthcare and investing in emerging markets, looking for solutions especially developed to address local needs.”

Philips said that between 2003 and 2006, growth in the Brazilian market for medical diagnostic imaging and monitoring equipment expanded at close to 20% per year, compared to annual growth rates in the global market of between 4% and 5%.

The Dutch company already holds what was characterized as a “prominent” position in the market for most types of medical imaging equipment. With the VMI acquisition, Philips will become a leader in general X-ray in Brazil.

Philips said it believes the move will further boost growth by capitalizing on VMI’s extensive distribution network. “Through this deal, we can build on VMI’s extensive sales and services channels in Brazil to further increase [our] access to local customers and provide a benefit to hospitals through a wider product portfolio,” said Daurio Speranzini, head of Philips in Latin America.

Philips said that the acquisition will give it the opportunity of producing both analogical and digital X-ray equipment in Brazil, offering “more affordable solutions” to the local market. Philips plans to boost VMI’s Brazilian exports to other countries in Latin America, which at the moment represent approximately 5% of VMI’s business.

Affymetrix SNP Array set for genome-wide study in Korea

Affymetrix (Santa Clara, California) said that South Korea’s National Institute of Health (KNIH) and Centers for Disease Control and Prevention will use the company’s Genome-Wide Human SNP Array 5.0 for the Korean Association REsource (KARE) project. SeouLin Bioscience will supply the Affymetrix microarray technology and will provide technical support to the Korea NIH.

The genome-wide association study is designed to identify the genetic causes of lifestyle-related complex diseases that are prevalent in South Korea. Affymetrix said the KARE project is expected to be “one of the world’s most recognizable clinical research projects.” Researchers will use the firm’s microarray technology to generate individual genotypes from more than 10,000 human DNA samples.

The SNP Array 5.0 is a single microarray featuring more than 500,000 single nucleotide polymorphisms (SNPs) and 420,000 additional non-polymorphic probes that can measure other genetic differences, such as copy number variation. Affymetrix said researchers are using the array to better identify and understand complex diseases such as autism, autoimmunity, bipolar disease, cancer, diabetes and heart disease.

The company said the technology “enables researchers to perform more powerful whole-genome association studies, increasing the probability of discovering genes associated with adverse drug response or complex disorders.” The resulting information will be made available as part of a database to help inspire additional research projects.

“Using the new Affymetrix SNP Array 5.0, we will be able to perform a true, unbiased genome-wide association study. This project will enable us to uncover the genes associated with diseases such as metabolic syndrome that affect many individuals in Korea,” said Bermseok Oh, PhD, chief, Division of Structural and Functional Genomics at KNIH. “We feel these studies can improve the quality of life by helping us develop cost-effective therapeutics and personalized preventative measures.”

The KARE project will use samples from the prospective epidemiological Ansan and Ansung cohorts in Korea. It is comparable to the SHARE (SNP Health Association REsource) project, a U.S.-based study that also is using Affymetrix technology to identify genetic variants associated with heart, lung, blood and sleep disorders.

In South Korea, the microarrays will be run in the high-throughput lab of DNA Link, an Affymetrix-certified service provider.

BrainLab warns of targeting error in devices

BrainLab (Munich, Germany) warned of malfunctions in devices that provide radiation treatments for brain cancer patients, saying the action involved a small targeting error that was “unlikely” to cause problems for patients. The French government ordered a shutdown of the equipment following the BrainLab warning.

The company downplayed the risks. Its founder and CEO Stefan Vilsmeier told the Associated Press that the action involved a “small targeting error” that was unlikely to cause problems for patients. But a company notification sent to a U.S. provider warned that injury or death could be caused by the malfunction.

BrainLab said the malfunction was believed to have occurred in just seven models in use worldwide. News reports indicated that four hospitals in France, two in the U.S. and one in Spain have the equipment.

One report quoted an official at the Cleveland Clinic, one of the affected centers, as saying the problem involves a small aiming error that can occur when BrainLab’s Novalis system is used with another manufacturer’s head frame, a ring-shaped device that circles the head and is used in delivering radiation.

He said the error involves a deviation of about 1.25 mm, similar to variations inherent in the delivery system, and added that he did not believe it would lead to serious problems.

BrainLab’s Vilsmeier said that because doctors typically allow a margin of error in targeting a tumor with radiation, “We don’t expect any problems with the patients.”

German firm acquires 50% of U.S. contract manufacturer

BIT Analytical Instruments (Schwalbach, Germany) has acquired a 50% equity investment in contract manufacturing services (CMS) firm Source Scientific (Irvine, California).

BIT is described as the European market leader in providing complete CMS, as well as product development and after-sales services to medical and industrial instrument original equipment manufacturer clients.

As part of the investment, BIT has acquired the 30% equity ownership position in Source Scientific held by Pressure BioSciences (Bridgewater, Massachusetts) since 2004. Source Scientific will continue to provide engineering, manufacturing and other related services for Pressure BioSciences.

“BIT’s strategic investment in our company will help to fuel our growth globally and capitalize on the surge in demand for outsourced medical devices and clinical instruments manufacturing,” said Richard Henson, president/CEO of Source Scientific. “We anticipate that Source Scientific will grow 10-fold over the next five years. This is a time of rapid expansion for our industry sector, and we’re poised to capitalize on industry trends.”

“Clients like Atherotech [Birmingham, Alabama], Hitachi Chemical Diagnostics [Mountain View, California] and Mettler Electronics [Anaheim, California] rely on outsourced partners to do what we do best - prototyping, manufacturing, shipping and customer support — so that they can focus on their core competencies of product development and marketing,” Henson said. He said BIT, which also has U.S. facilities in the Boston area, complements Source Scientific’s business model because of its strength in manufacturing complex medical instruments and its global market share position.

“The arrangement between BIT and Source Scientific creates a perfect partnership,” said Marius Balger, CEO and president of BIT. “Source Scientific’s strength is in engineering and partnering with clients to bring ideas to market, while BIT excels in manufacturing. As a result, the client can take advantage of a single relationship to reduce its manufacturing costs and supply-chain expenses while driving innovation and time to market.”

Quintiles establishes product development business ‘home’ in Scotland

Quintiles Transnational (Research Triangle Park, North Carolina) said it will build a new office near Edinburgh that will be the Scotland home for its Product Development business, including Quintiles Laboratories, and its NovaQuest group. The company said it will add 150 jobs in Scotland over the next four years.

The new 112,000-square-foot structure — which Quintiles could expand to 132,000 square feet — will be built in Livingston, West Lothian, near the firm’s present 36,500-square-foot laboratory. The new building will provide about 80,000 square feet of space for the laboratory business.

Quintiles’ Product Development and NovaQuest personnel occupy about 25,000 square feet in a Bathgate office, and those units also will move into the new building. Quintiles has 390 employees in the two locations.

“Our lab business is expanding — globally and in Europe — because of our proximity to clinical trial sites and our tight quality control,” said Thomas Wollman, senior VP, global central laboratories. “This new facility will enhance our level of customer service in the UK and Europe, just as our new central lab in Mumbai has improved service in India. We will continue to look for opportunities to strengthen our global central lab network.”

Stanford, government of India set up new biodesign program

The Stanford University Program in Biodesign (Stanford, California) is partnering with the government of India to establish a new training program, Stanford-India Biodesign, to create the next generation of biomedical technology innovators in India.

Harry Greenberg, MD, senior associate dean for research at the Stanford University School of Medicine, described the partnership as a plan to meet the future needs of India’s medical technology industry, which is poised to grow dramatically.

The Indian government said it would allocate $4.8 million over the next five years to help fund the joint venture between Stanford and India’s department of biotechnology to train future medical device inventors and catalyze the expansion of the medical technology industry in India.

The plan is to bring the Stanford program’s method of “teaching innovation” to Indian engineering, business and medical students through a two-year fellowship pilot project.

The fellowship will start with hands-on innovation training at Stanford and progress to immersion in health clinics and hospitals in India, where students will identify unmet medical needs specifically targeted for the Indian healthcare environment and create cost-effective solutions to meet those needs.

At the end of the program, the fellows will remain in India and lead the further development and testing of their solutions in a university program, start-up company or a new unit of an existing company.

While Stanford said its biodesign program “has successfully trained medical innovators with its unique methods of immersion in clinical settings and hands-on innovation for years,” the new partnership will emphasize the cost-effectiveness of the technology more than it has in the past.

German firm acquires 50% of U.S. contract manufacturer

BIT Analytical Instruments (Schwalbach, Germany) has acquired a 50% equity investment in contract manufacturing services (CMS) firm Source Scientific (Irvine, California).

BIT is described as the European market leader in providing complete CMS, as well as product development and after-sales services to medical and industrial instrument original equipment manufacturer clients.

As part of the investment, BIT has acquired the 30% equity ownership position in Source Scientific held by Pressure BioSciences (Bridgewater, Massachusetts) since 2004. Source Scientific will continue to provide engineering, manufacturing and other related services for Pressure BioSciences.

ReGen Biologics highlights meniscus implant at show

The European subsidiary of ReGen Biologics (Franklin Lakes, New Jersey) used this week’s congress of the International Society of Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine (ISAKOS; San Ramon, California) in Florence, Italy, to sponsor several events.

ReGen exhibited its flagship product, the CMI meniscus implant, which is CE-marked and cleared for sale in Europe for both medial and lateral use. The lateral CMI has been the subject of a post-marketing study in Europe since receiving the CE mark in 2006 and now will be available for general sale, the company said.

ReGen’s collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. The company’s first approved product using that technology is the CMI, which is cleared for sale in Europe and marketed through ReGen’s European subsidiary, ReGen Biologics AG.

Abbott molecular wins OK for hepatitis B viral load PCR test

Abbott Molecular (Des Plaines, Illinois) and Celera (Rockville, Maryland) said that Abbott has received CE-marking for a real-time polymerase chain reaction (PCR) test for monitoring hepatitis B (HBV) viral load in patients, allowing the test to be marketed in the European Union. Abbott is marketing the test under its alliance with Celera.

The Abbott RealTime HBV test, developed for use on the Abbott m2000 automated instrument system, is designed for the measurement of HBV in human plasma or serum from patients known to be infected with the virus. It is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of disease prognosis and as an aid in assessing a patient’s response to antiviral treatment.

With the addition of the HBV test, Abbott said the m2000 offers “the broadest menu of molecular tests available on a single instrument platform.” The m2000 menu includes real-time PCR tests for HIV-1, hepatitis C, Chlamydia, and a combination test for chlamydia and gonorrhea.

Abbott said quantitative measurements of HBV levels in plasma or serum have been shown to be “an essential parameter” in the prognosis and management of patients with HBV. An initial measurement of HBV viral load can guide a decision to begin antiviral therapy, while monitoring HBV DNA levels during therapy can influence its duration and also signal the development of drug resistance.

The higher the baseline viral level, the more likely a patient is to develop hepatocellular carcinoma, a primary cancer of the liver.

“The Abbott RealTime HBV assay is the only test currently available that targets an essential, highly conserved segment of the HBV genome, which makes it a very reliable test for detecting and measuring all known HBV genotypes,” said John Robinson, PhD, senior director, research and development, Abbott Molecular. “It gives physicians one of the most precise tests available to guide treatment decisions.”

Abbott currently markets the m2000 system and a menu of tests in countries throughout the world as part of a strategic alliance with Celera. In Europe, the instrument’s menu includes assays for HIV-1 viral load, HCV viral load, chlamydia, and a combination test for chlamydia and gonorrhea.

Celera is an Applera (Norwalk, Connecticut) business. Its molecular diagnostics business uses proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and the company is developing diagnostic products based on these markers as well as other known markers.

• OrSense (Nes Ziona, Israel) reported receiving CE-mark approval for its NBM-200G non-invasive continuous blood glucose monitor. The NBM-200G is based on OrSense’s proprietary technology that allows non-invasive measurement of analytes, including glucose, hemoglobin, and oxygen saturation with very high sensitivity.

The device is operated by placing a ring-shaped probe around the patient’s finger, which applies a gentle pressure to the finger, similar to that applied during blood-pressure measurement. Optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger.

Called Occlusion Spectroscopy, this method provides a quick, accurate and painless measurement of the patient’s blood glucose. OrSense said the method was tested on more than 400 patients and exhibited “comparable accuracy to invasive solutions, while providing superior ease of use and safety.”

The NBM-200G also enables the identification of glucose trends and the detection of hypo- and hyperglycemic events and according to the company, “may also optimally answer the growing need for tight glycemic control in acute-care settings, thereby reducing morbidity and mortality.”

Professor Avraham Karasik, director of the Institute of Endocrinology at Chaim Sheba Medical Center (Tel Hashomer, Israel), said, “We have been studying OrSense’s non-invasive continuous monitoring device on a significant number of patients in a home-like environment and in acute-care settings. The device’s performance is extremely robust and reliable, user compliance is very good with no adverse effects, and the results are promising.”

“This is an important milestone for OrSense in the path for developing the first fully non-invasive glucose monitoring device,” said Chairman Shimon Eckhouse, PhD. “This... will play a very significant role in improving the quality of life of millions of diabetic patients around the world.”

OrSense said its non-invasive device is “poised to provide a dramatic improvement in the quality of care and quality of life of people with diabetes,” allowing them to avoid the discomfort of traditional fingerstick-based methods.

An abstract containing data from clinical trails demonstrating the reliability of NBM-200G was accepted for a poster presentation titled “A Non-Invasive Prospective Continuous Glucose Monitoring System” during the 67th scientific session of the American Diabetes Association (Alexandria, Virginia) in Chicago, in June.

• InSightec (Haifa, Israel) reported that its ExAblate 2000 system has received the CE mark for pain palliation of bone metastases. The company said that 100,000 patients in Europe are diagnosed with bone metastases every year. Most cancer patients suffer from pain, so controlling it and managing its symptoms are important treatment goals.

In clinical studies that supported the CE mark certification, patients reported their pain levels using VAS (Visual Analog Score), a pain questionnaire used to monitor changes in pain levels and assess the efficacy of pain management.

The majority of patients reported an immediate improvement in pain scores, the company said. Many also reported that they stopped using any analgesic pain relief.

“ExAblate 2000 has been used to successfully treat uterine fibroids non-invasively with magnetic resonance-guided focused ultrasound (MRgFUS) and this second CE mark represents a significant milestone in our quest to expand the potential applications of this non-invasive therapy for oncology,” said Dr. Kobi Vortman, president and CEO of InSightec. “This procedure can alleviate the patient’s pain, has the potential to lower reliance on analgesics and provide patients with the opportunity for improved quality of life.”

The ExAblate 2000 is the first system to use the MRgFUS technology, which combines MRI (to visualize tissues in the body, plan the treatment and monitor in real time treatment outcome) and high-intensity focused ultrasound to thermally ablate uterine fibroid tissue.

• LinkMed’s (Stockholm, Sweden) portfolio company, SACS Medical, has been granted 510(k) clearance by the FDA for sales of its medical signal handling systems in the U.S.

“FDA clearance is a stamp of quality that will facilitate us in our search for an industrial partner for SACS Medical,” said Ingemar Lagerl f, CEO of LinkMed.

SACS Medical reports that its system for medical signal handling can handle EEG and EMG signals, among others. The system is used primarily by specialist clinics to diagnose, monitor and treat patients spread over a large geographical area from one centralized location.